Verimatrix to Ride the Waves of Innovation at IBC 2024 with Counterspy Showcase
Regulatory News:
Verimatrix, (Euronext Paris: VMX, FR0010291245), a global leader in powering the modern connected world with people-centered security, today announced its exciting plans for IBC 2024 taking place from September 13-17 in Amsterdam. Verimatrix’s IBC booth 1.C65 is set to become "Broadcast Beach," a vibrant, surf and sand-themed experience designed to transport attendees to the sunny shores of San Diego (home of Verimatrix’s U.S. office), while showcasing the company’s robust suite of security solutions, including its latest anti-piracy solution, Counterspy.
Counterspy, a new product in the Verimatrix Streamkeeper family, is a groundbreaking solution designed to tackle the escalating threat of digital video piracy in bold new ways. It offers unparalleled protection with a focus on tangible revenue-saving benefits for customers. IBC attendees will be able to experience a live demonstation that showcases how Counterspy customers can:
- Reduce Video Piracy: Counterspy provides a formidable defense against unauthorized access, significantly cutting down on piracy incidents and securing content across platforms.
- Protect Media Apps: With its advanced app protection and telemetry features, Counterspy shields media apps from reverse engineering, man-in-the-middle attacks, and other malicious activities, ensuring that only legitimate users can access content – and providing customers with a way to monitor and respond to piracy threats in real-time.
- Unlock Access to More Premium Content: By safeguarding content with Counterspy, operators can confidently expand their premium content offerings, meeting studio security requirements.
- Reduce CDN Costs: Counterspy directly addresses the issue of CDN leeching, enabling operators to cut CDN costs dramatically (one Verimatrix customer saw their CDN expenses drop by 50% after implementing Counterspy)
- Boost Paid Subscribers: By enhancing content security and reducing piracy, Counterspy helps customers maintain a trustworthy service vs. pirate services, which in turn helps drive subscriber growth and revenue.
The Verimatrix Broadcast Beach-themed booth at IBC 2024 will feature:
- Surfside Check-In: The first stop in the serene beachfront oasis where attendees can check in with a host and grab some wave-breaking Verimatrix swag.
- Counterspy Cove: Grab a seat at one of the high-back deck tables and interact with a live demo for Verimatrix Counterspy, the ultimate in video security defense, seamlessly shielding media apps from piracy, preventing CDN leeching, reducing credential theft, and ensuring substantial revenue protection.
- Revenue Protection Cabanas: Reserve a cabana equipped with hammocks and interactive displays to comfortably engage with and learn about award-winning Verimatrix Streamkeeper solutions.
- Cyber Surf Shack: Dive into a surf-themed espresso bar adorned with surfboards and beach cruisers, symbolizing Verimatrix’s agility and adaptability.
Attendees are invited to kick off their shoes and soak up some fun in the sun while staff from Verimatrix highlight the latest in secure streaming, bulletproof cybersecurity, and layered anti-piracy measures. To book at meeting with a Verimatrix security specialist during IBC 2024, email dvanmeter@verimatrix.com or alternatively, book a meeting online.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903597006/en/
Contacts
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Mathilde Guillemot-Costes
mathilde.guillemot@seitosei-actifin.com
Michael Scholze
Michael.scholze@seitosei-actifin.com
Verimatrix Media Contacts:
Matthew Zintel, Zintel Public Relations
matthew.zintel@zintelpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Expands Nordic Reach with New Office in Sweden9.9.2024 08:19:00 CEST | Press release
Global technology corporation FPT recently announced the opening of its first office in Stockholm, Sweden. This strategic move is driven by the country's increasing demand for digital services and high-quality IT professionals in its critical areas, including healthcare, automotive, banking and finance, and green transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240908210868/en/ The inauguration ceremony took place during the Vietnam-Sweden Business Forum in Stockholm, Sweden. (Photo: Business Wire) Located in Lindholmen Science Park, Gothenburg, Sweden's leading innovation hub, with a vibrant ecosystem of over 375 leading companies, FPT's new office positions the company closer to industry giants, particularly those in the automotive, energy, and manufacturing domains, such as Volvo Group, Ericsson, Telia, SAAB, IBM, and Semcon. This strategic location thereby allows FPT to enhance its ability to expand its loc
ArcanaBio Secures Funding from BioInnovation Institute to Revolutionize Healthcare with new Ultra-Rapid Liquid Biopsy Technology9.9.2024 08:15:00 CEST | Press release
ArcanaBio, a pioneering biotech company, is proud to announce its selection for funding by Denmark’s BioInnovation Institute (BII), supported by the Novo Nordisk Foundation. ArcanaBio will join BII’s Deep Tech Lab – Quantum program in Copenhagen from September 2024. “We are honoured to receive funding and to be selected to join this prestigious quantum initiative,” said Kristjan Gunnarsson, CEO of ArcanaBio. “We are at the forefront of a new biosensor revolution with a patent-pending, label-free detection technology that has been a long-sought-after advancement in proteomics. Our novel platform has potential both to enable testing laboratories to offer a wider range of biomarker services at lower cost and empower individuals to proactively monitor their health by integrating frequent, reference-quality testing into their lives.” “The goal here is to rethink diagnostics. Building a new capability to track proteome dynamics can provide powerful real-time and predictive insights into heal
Saint-Denis Hospital Center in France Implements Masimo SafetyNet ® Telemonitoring to Facilitate Early Discharge of Premature Newborns from the Hospital9.9.2024 08:00:00 CEST | Press release
Masimo (NASDAQ: MASI) today announced that Saint-Denis Hospital Center is adopting the use of the Masimo SafetyNet® cloud-based telemonitoring platform as part of an experimental mobile neonatology unit aimed at facilitating earlier discharge of premature newborns from the ICU to the home. Launched in February, this pioneering project allows vulnerable neonates to return home safely to their families while remaining under the close supervision of the hospital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240908136612/en/ Masimo SafetyNet® and Saint-Denis Hospital Center, Delafontaine (France) (Photo: Business Wire) Masimo SafetyNet offers a streamlined approach to remote patient management that can be scaled and tailored to each patient’s unique care needs, offering wireless continuous monitoring and spot-check devices, customizable CarePrograms™ with symptom reporting, and a secure in-hospital clinical portal that allows
Epsilogen Completes £12.5 Million Series B Financing Expansion9.9.2024 08:00:00 CEST | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the completion of a £12.5 million Series B expansion financing bringing the Series B total to £43.25 million. This financing will fund the delivery of clinical Proof of Concept for lead asset MOv18 IgE in a phase Ib trial featuring platinum-resistant ovarian cancer (PROC) as well as further development of the company’s IgE-based pipeline. The financing was entirely conducted by existing investors including British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund and ALSA Ventures. MOv18 IgE is the first therapeutic IgE antibody to enter the clinic. This first-in-class antibody targets folate receptor alpha (FRα), an antigen present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. In a phase I trial, MOv18 IgE was found to be safe and well tolerated with initial signs of clinical activity also se
BeiGene Highlights TEVIMBRA ® Data in Lung and Gastrointestinal Cancers at ESMO 20249.9.2024 07:00:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, September 13-17, 2024. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special session revisiting the ESMO Virtual Plenary held in February 2024. New Data Add to Evidence for TEVIMBRA Across Multiple Disease States As an encore to the ESMO plenary, interim results from the RATIONALE-315 study show the statistically significant event-free survival (EFS) and trend for overall survival (OS) benefit favoring neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab vs. placebo plus chemotherapy with adjuvant placebo for patients with resectable non-small cell lung cancer (NSCLC) (session #VP1-2024, Sept. 13 from 4:17-4:29 p.m. CEST). These results further reinforce the data presented at ESMO 2023 showing major p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom